Novartis presented Phase III VAYHIT2 data showing ianalumab, added to eltrombopag, extended disease control in primary immune thrombocytopenia (ITP) and reduced treatment failure by 45% at the higher dose. The randomized trial enrolled 152 patients and showed a median time to treatment failure of 13 months for high‑dose ianalumab versus 4.7 months for placebo. The antibody, which targets the BAFF receptor to deplete autoreactive B cells, was presented at ASH and published in the New England Journal of Medicine. Investigators reported comparable adverse event rates across arms and highlighted the potential for finite‑course immunotherapy to deliver prolonged remission in ITP. Clarification: ITP is an autoimmune disorder where antibody‑mediated platelet destruction causes bleeding risk; extending remission without continuous therapy could materially change chronic disease management.